Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2007

View Archived Issues

Summary of studies evaluating the effect of various natural products on diabetes

Profile of the antithrombotic agent rivaroxaban

Preclinical studies characterize the antithrombotic effect of MCC-977

Rapid, high-level platelet inhibition seen with PRT-060128 in humans

Antithrombotic activity seen with TGX-221 in vivo

Withaferin A holds promise as a potential drug lead

Alkaline phosphatase shows promise in ulcerative colitis

Peregrine acquires rights to antiangiogenesis technology from M.D. Anderson

ADL-5859 begins phase II pain study

Enrollment completed in phase II cardiovascular restenosis trial of Resten-MP

GRN-163L begins phase I/II study in advanced NSCLC

Biologics Menoflavon launched in Canada

Recent patents disclose novel antiinfective agents

DSM and Crucell sign licensing agreement with Masterclone to develop antibody

NPS and Nycomed expand Preotact agreement

Update on Karo Bio and Merck collaboration

CV Therapeutics identifies potential first-in-class MOA for ranolazine

Gilead initiates expanded access program for aztreonam lysine for CF

CB-7630 shows activity in prostate cancer trials

Nimotuzumab shown to bind to EGF receptor and potentiate radiotherapy

U.S. orphan drug designation for Corlux in Cushing's syndrome

New agents for gastrointestinal disorders described in recent patents

Zybrestat begins pivotal study in anaplastic thyroid cancer

Novel analgesic agents imparted in recent patent literature

NV-1020 shows promise in metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...